US1073811A
(en)
|
1913-04-24 |
1913-09-23 |
Carl G Miller |
Fly-trap.
|
JPS5144499B1
(xx)
|
1970-08-29 |
1976-11-29 |
|
|
JPS5334319B2
(xx)
|
1971-12-28 |
1978-09-20 |
|
|
JPS5717624B2
(xx)
|
1974-04-17 |
1982-04-12 |
|
|
US4208479A
(en)
|
1977-07-14 |
1980-06-17 |
Syva Company |
Label modified immunoassays
|
US4474893A
(en)
|
1981-07-01 |
1984-10-02 |
The University of Texas System Cancer Center |
Recombinant monoclonal antibodies
|
US4444878A
(en)
|
1981-12-21 |
1984-04-24 |
Boston Biomedical Research Institute, Inc. |
Bispecific antibody determinants
|
JPS58201994A
(ja)
|
1982-05-21 |
1983-11-25 |
Hideaki Hagiwara |
抗原特異的ヒト免疫グロブリンの生産方法
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
GB8607679D0
(en)
|
1986-03-27 |
1986-04-30 |
Winter G P |
Recombinant dna product
|
JPH0234615Y2
(xx)
|
1986-08-08 |
1990-09-18 |
|
|
US5260203A
(en)
*
|
1986-09-02 |
1993-11-09 |
Enzon, Inc. |
Single polypeptide chain binding molecules
|
JPS63149900A
(ja)
|
1986-12-15 |
1988-06-22 |
Toshiba Corp |
半導体メモリ
|
US4851341A
(en)
|
1986-12-19 |
1989-07-25 |
Immunex Corporation |
Immunoaffinity purification system
|
US5004697A
(en)
|
1987-08-17 |
1991-04-02 |
Univ. Of Ca |
Cationized antibodies for delivery through the blood-brain barrier
|
JPH01144991A
(ja)
|
1987-12-02 |
1989-06-07 |
Kagaku Oyobi Ketsusei Riyouhou Kenkyusho |
血液凝固第8因子の精製方法
|
US5670373A
(en)
*
|
1988-01-22 |
1997-09-23 |
Kishimoto; Tadamitsu |
Antibody to human interleukin-6 receptor
|
US5322678A
(en)
|
1988-02-17 |
1994-06-21 |
Neorx Corporation |
Alteration of pharmacokinetics of proteins by charge modification
|
US6010902A
(en)
|
1988-04-04 |
2000-01-04 |
Bristol-Meyers Squibb Company |
Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity
|
JPH0250497A
(ja)
|
1988-08-12 |
1990-02-20 |
Tokin Corp |
電波吸収体とその製造方法
|
US5126250A
(en)
*
|
1988-09-28 |
1992-06-30 |
Eli Lilly And Company |
Method for the reduction of heterogeneity of monoclonal antibodies
|
BG60017B2
(en)
|
1988-09-28 |
1993-06-30 |
Lilly Co Eli |
Method for reducing the heterogeneity of monoclonal antibodies
|
IL89491A0
(en)
|
1988-11-17 |
1989-09-10 |
Hybritech Inc |
Bifunctional chimeric antibodies
|
DE3920358A1
(de)
|
1989-06-22 |
1991-01-17 |
Behringwerke Ag |
Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
|
GB8916400D0
(en)
|
1989-07-18 |
1989-09-06 |
Dynal As |
Modified igg3
|
JPH0636741B2
(ja)
|
1989-11-08 |
1994-05-18 |
帝人株式会社 |
ヒト・プロテインcの分離方法
|
ATE177321T1
(de)
|
1989-12-11 |
1999-03-15 |
Immunomedics Inc |
Verfahren zum aufspüren von diagnostischen oder therapeutischen mitteln durch antikörper
|
US5859205A
(en)
|
1989-12-21 |
1999-01-12 |
Celltech Limited |
Humanised antibodies
|
US5130129A
(en)
|
1990-03-06 |
1992-07-14 |
The Regents Of The University Of California |
Method for enhancing antibody transport through capillary barriers
|
TW212184B
(xx)
|
1990-04-02 |
1993-09-01 |
Takeda Pharm Industry Co Ltd |
|
JPH05184383A
(ja)
|
1990-06-19 |
1993-07-27 |
Dainabotsuto Kk |
二重特異性抗体
|
CA2109602C
(en)
|
1990-07-10 |
2002-10-01 |
Gregory P. Winter |
Methods for producing members of specific binding pairs
|
GB9015198D0
(en)
|
1990-07-10 |
1990-08-29 |
Brien Caroline J O |
Binding substance
|
JPH05199894A
(ja)
|
1990-08-20 |
1993-08-10 |
Takeda Chem Ind Ltd |
二重特異性抗体および抗体含有薬剤
|
EP0814159B1
(en)
|
1990-08-29 |
2005-07-27 |
GenPharm International, Inc. |
Transgenic mice capable of producing heterologous antibodies
|
ES2134212T3
(es)
*
|
1991-04-25 |
1999-10-01 |
Chugai Pharmaceutical Co Ltd |
Anticuerpo humano reconstituido contra el receptor de la interleuquina 6 humano.
|
JPH05304992A
(ja)
|
1991-06-20 |
1993-11-19 |
Takeda Chem Ind Ltd |
ハイブリッド・モノクローナル抗体および抗体含有薬剤
|
US5468634A
(en)
*
|
1991-06-24 |
1995-11-21 |
The University Of North Carolina At Chapel Hill |
Axl oncogene
|
US6136310A
(en)
|
1991-07-25 |
2000-10-24 |
Idec Pharmaceuticals Corporation |
Recombinant anti-CD4 antibodies for human therapy
|
EP0605522B1
(en)
|
1991-09-23 |
1999-06-23 |
Medical Research Council |
Methods for the production of humanized antibodies
|
ES2165851T3
(es)
|
1991-11-25 |
2002-04-01 |
Enzon Inc |
Proteinas multivalentes que se unen a antigenos.
|
ATE463573T1
(de)
|
1991-12-02 |
2010-04-15 |
Medimmune Ltd |
Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
|
AU3328493A
(en)
|
1991-12-17 |
1993-07-19 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
US5667988A
(en)
|
1992-01-27 |
1997-09-16 |
The Scripps Research Institute |
Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
|
JPH05203652A
(ja)
|
1992-01-28 |
1993-08-10 |
Fuji Photo Film Co Ltd |
抗体酵素免疫分析法
|
JPH05213775A
(ja)
|
1992-02-05 |
1993-08-24 |
Otsuka Pharmaceut Co Ltd |
Bfa抗体
|
US6749853B1
(en)
|
1992-03-05 |
2004-06-15 |
Board Of Regents, The University Of Texas System |
Combined methods and compositions for coagulation and tumor treatment
|
JP3507073B2
(ja)
|
1992-03-24 |
2004-03-15 |
ケンブリッジ アンティボディー テクノロジー リミティド |
特異的結合対の成員の製造方法
|
US6129914A
(en)
|
1992-03-27 |
2000-10-10 |
Protein Design Labs, Inc. |
Bispecific antibody effective to treat B-cell lymphoma and cell line
|
US5744446A
(en)
|
1992-04-07 |
1998-04-28 |
Emory University |
Hybrid human/animal factor VIII
|
EP0640094A1
(en)
|
1992-04-24 |
1995-03-01 |
The Board Of Regents, The University Of Texas System |
Recombinant production of immunoglobulin-like domains in prokaryotic cells
|
NZ255101A
(en)
|
1992-07-24 |
1997-08-22 |
Cell Genesys Inc |
A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor
|
ZA936260B
(en)
|
1992-09-09 |
1994-03-18 |
Smithkline Beecham Corp |
Novel antibodies for conferring passive immunity against infection by a pathogen in man
|
US5639641A
(en)
|
1992-09-09 |
1997-06-17 |
Immunogen Inc. |
Resurfacing of rodent antibodies
|
BR9204244A
(pt)
|
1992-10-26 |
1994-05-03 |
Cofap |
Ferro fundido cinzento
|
RU2151612C1
(ru)
|
1992-12-01 |
2000-06-27 |
Протеин Дизайн Лэбс, Инк. |
Гуманизированный иммуноглобулин, специфичный для белка l-селектина человека
|
US5837242A
(en)
|
1992-12-04 |
1998-11-17 |
Medical Research Council |
Multivalent and multispecific binding proteins, their manufacture and use
|
JPH09507829A
(ja)
|
1993-03-19 |
1997-08-12 |
ジョーンズ ホプキンス ユニバーシティー スクール オブ メディシン |
増殖分化因子−8
|
US7393682B1
(en)
|
1993-03-19 |
2008-07-01 |
The Johns Hopkins University School Of Medicine |
Polynucleotides encoding promyostatin polypeptides
|
GB9313509D0
(en)
|
1993-06-30 |
1993-08-11 |
Medical Res Council |
Chemisynthetic libraries
|
EP0660937A1
(en)
|
1993-07-01 |
1995-07-05 |
Dade International Inc. |
Process for the preparation of factor x depleted plasma
|
GB9314271D0
(en)
|
1993-07-09 |
1993-08-18 |
Inst Of Cancer The Research |
Cell growth factor receptors
|
UA40577C2
(uk)
|
1993-08-02 |
2001-08-15 |
Мерк Патент Гмбх |
Біспецифічна молекула, що використовується для лізису пухлинних клітин, спосіб її одержання, моноклональне антитіло (варіанти), фармацевтичний препарат, фармацевтичний набір (варіанти), спосіб видалення пухлинних клітин
|
IL107742A0
(en)
|
1993-11-24 |
1994-02-27 |
Yeda Res & Dev |
Chemically-modified binding proteins
|
US6214613B1
(en)
|
1993-12-03 |
2001-04-10 |
Ashai Kasei Kogyo Kabushiki Kaisha |
Expression screening vector
|
WO1995015388A1
(en)
|
1993-12-03 |
1995-06-08 |
Medical Research Council |
Recombinant binding proteins and peptides
|
US6074642A
(en)
|
1994-05-02 |
2000-06-13 |
Alexion Pharmaceuticals, Inc. |
Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
|
DE4419399C1
(de)
|
1994-06-03 |
1995-03-09 |
Gsf Forschungszentrum Umwelt |
Verfahren zur Herstellung von heterologen bispezifischen Antikörpern
|
US5945311A
(en)
*
|
1994-06-03 |
1999-08-31 |
GSF--Forschungszentrumfur Umweltund Gesundheit |
Method for producing heterologous bi-specific antibodies
|
US8017121B2
(en)
*
|
1994-06-30 |
2011-09-13 |
Chugai Seiyaku Kabushika Kaisha |
Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
|
NZ288883A
(en)
|
1994-07-11 |
1998-12-23 |
Univ Texas |
Conjugates comprising coagulation factors
|
TW416960B
(en)
|
1994-07-13 |
2001-01-01 |
Chugai Pharmaceutical Co Ltd |
Reshaped human antibody to human interleukin-8
|
DE69535243T2
(de)
|
1994-07-13 |
2007-05-10 |
Chugai Seiyaku K.K. |
Gegen menschliches interleukin-8 gerichteter, rekonstituierter menschlicher antikörper
|
US6048972A
(en)
|
1994-07-13 |
2000-04-11 |
Chugai Pharmaceutical Co., Ltd. |
Recombinant materials for producing humanized anti-IL-8 antibodies
|
JP3865418B2
(ja)
|
1994-07-13 |
2007-01-10 |
中外製薬株式会社 |
ヒトインターロイキン−8に対する再構成ヒト抗体
|
US6309636B1
(en)
|
1995-09-14 |
2001-10-30 |
Cancer Research Institute Of Contra Costa |
Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides
|
EP2077120A3
(en)
|
1994-10-07 |
2009-07-15 |
Chugai Seiyaku Kabushiki Kaisha |
Rheumatoid arthritis remedy containing il-6 antagonist as active ingredient
|
HU227708B1
(en)
|
1994-10-21 |
2011-12-28 |
Chugai Pharmaceutical Co Ltd |
Use of anti-interleukin-6-receptor antibodies mr-16 and pm-1 and derivatives thereof for producing pharmaceutical preparation for treating diseases caused by il-6 production
|
EP1241264A1
(en)
|
1994-12-02 |
2002-09-18 |
Chiron Corporation |
Monoclonal antibodies to colon cancer antigen
|
US6485943B2
(en)
|
1995-01-17 |
2002-11-26 |
The University Of Chicago |
Method for altering antibody light chain interactions
|
US5876950A
(en)
|
1995-01-26 |
1999-03-02 |
Bristol-Myers Squibb Company |
Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
|
BR9604884A
(pt)
|
1995-02-28 |
1998-05-19 |
Procter & Gamble |
Preparação de produtos de bebida não carbonatada com estabilidade microbiana superior
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
JP4312259B2
(ja)
|
1995-04-27 |
2009-08-12 |
アムジェン フレモント インク. |
免疫したゼノマウス(XenoMouse)に由来するヒト抗体
|
WO1996034096A1
(en)
|
1995-04-28 |
1996-10-31 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
KR100259828B1
(ko)
|
1995-09-11 |
2000-06-15 |
히라타 다다시 |
인체 인터루킨 5 수용체 알파-사슬에 대한 항체
|
MA24512A1
(fr)
|
1996-01-17 |
1998-12-31 |
Univ Vermont And State Agrienl |
Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose
|
CA2249195A1
(en)
|
1996-03-18 |
1997-09-25 |
Board Of Regents, The University Of Texas System |
Immunoglobin-like domains with increased half lives
|
JP3032287U
(ja)
|
1996-06-10 |
1996-12-17 |
幸喜 高橋 |
人 形
|
US20020147326A1
(en)
|
1996-06-14 |
2002-10-10 |
Smithkline Beecham Corporation |
Hexameric fusion proteins and uses therefor
|
EP0938499A1
(en)
*
|
1996-07-19 |
1999-09-01 |
Amgen Inc. |
Analogs of cationic proteins
|
EP0918872B1
(en)
|
1996-08-02 |
2008-02-20 |
Bristol-Myers Squibb Company |
A method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis
|
US7247302B1
(en)
|
1996-08-02 |
2007-07-24 |
Bristol-Myers Squibb Company |
Method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis
|
RU2198220C2
(ru)
|
1996-09-26 |
2003-02-10 |
Чугаи Сейяку Кабусики Кайся |
Антитело против белка, родственного паращитовидному гормону человека, днк, вектор, способ получения и использование антитела
|
JPH10165184A
(ja)
|
1996-12-16 |
1998-06-23 |
Tosoh Corp |
抗体、遺伝子及びキメラ抗体の製法
|
US5990286A
(en)
|
1996-12-18 |
1999-11-23 |
Techniclone, Inc. |
Antibodies with reduced net positive charge
|
US6277375B1
(en)
|
1997-03-03 |
2001-08-21 |
Board Of Regents, The University Of Texas System |
Immunoglobulin-like domains with increased half-lives
|
DK2011514T3
(da)
|
1997-03-21 |
2012-03-26 |
Chugai Pharmaceutical Co Ltd |
Forebyggende eller terapeutisk middel til sensibiliserede-T-celle-medierede sygdomme omfattende IL-6-antagonist som en aktiv bestanddel
|
US20070059302A1
(en)
*
|
1997-04-07 |
2007-03-15 |
Genentech, Inc. |
Anti-vegf antibodies
|
US6884879B1
(en)
*
|
1997-04-07 |
2005-04-26 |
Genentech, Inc. |
Anti-VEGF antibodies
|
FR2761994B1
(fr)
|
1997-04-11 |
1999-06-18 |
Centre Nat Rech Scient |
Preparation de recepteurs membranaires a partir de baculovirus extracellulaires
|
US20030207346A1
(en)
|
1997-05-02 |
2003-11-06 |
William R. Arathoon |
Method for making multispecific antibodies having heteromultimeric and common components
|
US20020062010A1
(en)
|
1997-05-02 |
2002-05-23 |
Genentech, Inc. |
Method for making multispecific antibodies having heteromultimeric and common components
|
DE69830901T2
(de)
|
1997-05-02 |
2006-05-24 |
Genentech Inc., San Francisco |
ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen
|
DE19725586C2
(de)
|
1997-06-17 |
1999-06-24 |
Gsf Forschungszentrum Umwelt |
Verfahren zur Herstellung von Zellpräparaten zur Immunisierung mittels heterologer intakter bispezifischer und/oder trispezifischer Antikörper
|
US5980893A
(en)
|
1997-07-17 |
1999-11-09 |
Beth Israel Deaconess Medical Center, Inc. |
Agonist murine monoclonal antibody as a stimulant for megakaryocytopoiesis
|
US6207805B1
(en)
|
1997-07-18 |
2001-03-27 |
University Of Iowa Research Foundation |
Prostate cell surface antigen-specific antibodies
|
DK1004315T3
(da)
|
1997-08-15 |
2008-07-21 |
Chugai Pharmaceutical Co Ltd |
Forebyggende midler og/eller lægemidler indeholdende anti-IL6-receptorneutraliserende antistoffer til reduktion af urinproteinudskillelsen ved systemisk lupus erythematosus
|
US20020187150A1
(en)
*
|
1997-08-15 |
2002-12-12 |
Chugai Seiyaku Kabushiki Kaisha |
Preventive and/or therapeutic agent for systemic lupus erythematosus comprising anti-IL-6 receptor antibody as an active ingredient
|
US6342220B1
(en)
|
1997-08-25 |
2002-01-29 |
Genentech, Inc. |
Agonist antibodies
|
WO1999018212A1
(fr)
|
1997-10-03 |
1999-04-15 |
Chugai Seiyaku Kabushiki Kaisha |
Anticorps humain naturel
|
RU2195960C2
(ru)
*
|
1998-03-17 |
2003-01-10 |
Тугаи Сейяку Кабусики Кайся |
Профилактический или терапевтический агент для лечения воспалительных заболеваний кишечника, содержащий в качестве активного ингредиента антагонист il-6
|
ES2532910T3
(es)
|
1998-04-02 |
2015-04-01 |
Genentech, Inc. |
Variantes de anticuerpos y fragmentos de los mismos
|
PL343322A1
(en)
|
1998-04-03 |
2001-08-13 |
Chugai Pharmaceutical Co Ltd |
Humanized antibody against human tissue factor (tf) and process for constructing humanized antibody
|
GB9809951D0
(en)
|
1998-05-08 |
1998-07-08 |
Univ Cambridge Tech |
Binding molecules
|
WO2000009560A2
(en)
|
1998-08-17 |
2000-02-24 |
Abgenix, Inc. |
Generation of modified molecules with increased serum half-lives
|
US6329511B1
(en)
*
|
1998-12-01 |
2001-12-11 |
Protein Design Labs, Inc. |
Humanized antibodies to γ-interferon
|
WO2000034317A2
(en)
|
1998-12-08 |
2000-06-15 |
Biovation Limited |
Method for reducing immunogenicity of proteins
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
MXPA01007170A
(es)
|
1999-01-15 |
2002-07-30 |
Genentech Inc |
Variantes de polipeptidos con funcion efectora alterada.
|
US7183387B1
(en)
|
1999-01-15 |
2007-02-27 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
US6972125B2
(en)
*
|
1999-02-12 |
2005-12-06 |
Genetics Institute, Llc |
Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith
|
WO2004009618A2
(en)
|
2002-07-18 |
2004-01-29 |
Crucell Holland B.V. |
Recombinant production of mixtures of antibodies
|
ATE455852T1
(de)
|
1999-06-02 |
2010-02-15 |
Chugai Pharmaceutical Co Ltd |
Neues hämopoietin rezeptorprotein nr10
|
SK782002A3
(en)
*
|
1999-07-21 |
2003-08-05 |
Lexigen Pharm Corp |
FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
AT411997B
(de)
|
1999-09-14 |
2004-08-26 |
Baxter Ag |
Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate
|
SE9903895D0
(sv)
|
1999-10-28 |
1999-10-28 |
Active Biotech Ab |
Novel compounds
|
US20020164668A1
(en)
*
|
2000-04-03 |
2002-11-07 |
Durham L. Kathryn |
Nucleic acid molecules, polypeptides and uses therefor, including diagnosis and treatment of alzheimer's disease
|
CA2407460C
(en)
|
2000-04-28 |
2013-06-25 |
Sangamo Biosciences, Inc. |
Targeted modification of chromatin structure
|
AU6627201A
(en)
*
|
2000-05-03 |
2001-11-12 |
Mbt Munich Biotechnology Gmbh |
Cationic diagnostic, imaging and therapeutic agents associated with activated vascular sites
|
JP2004511430A
(ja)
|
2000-05-24 |
2004-04-15 |
イムクローン システムズ インコーポレイティド |
二重特異性免疫グロブリン様抗原結合蛋白および製造方法
|
AU2001271066A1
(en)
|
2000-07-17 |
2002-01-30 |
Chugai Seiyaku Kabushiki Kaisha |
Method for screening ligand having biological activity
|
AU2011244851A1
(en)
|
2000-07-27 |
2011-11-24 |
The John Hopkins University School Of Medicine |
Promyostatin peptides and methods of using same
|
DK1325033T3
(da)
|
2000-10-10 |
2010-04-06 |
Genentech Inc |
Inhibering af komplement C5 aktivering til behandlingen og forebyggelsen af forsinket xenograf- eller akut vaskulær afstødning
|
EP2116265B1
(en)
|
2000-10-12 |
2020-12-23 |
Genentech, Inc. |
Reduced-viscosity concentrated protein formulations
|
WO2002033073A1
(fr)
|
2000-10-20 |
2002-04-25 |
Chugai Seiyaku Kabushiki Kaisha |
Anticorps agoniste degrade
|
ES2298273T3
(es)
|
2000-10-25 |
2008-05-16 |
Chugai Seiyaku Kabushiki Kaisha |
Agentes preventivos o terapeuticos contra la psoriasis que contienen un antagonista de il-6 como su ingrediente activo.
|
WO2002036165A1
(fr)
*
|
2000-10-27 |
2002-05-10 |
Chugai Seiyaku Kabushiki Kaisha |
Agent à base d'antagoniste d'il-6, faisant baisser le niveau des mmp-3 dans le sang
|
JP4336498B2
(ja)
|
2000-12-12 |
2009-09-30 |
メディミューン,エルエルシー |
延長した半減期を有する分子ならびにその組成物および用途
|
PT1366067E
(pt)
|
2001-03-07 |
2012-11-29 |
Merck Patent Gmbh |
Tecnologia de expressão para proteínas contendo uma unidade de anticorpo de isotipo híbrido
|
UA80091C2
(en)
|
2001-04-02 |
2007-08-27 |
Chugai Pharmaceutical Co Ltd |
Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
|
DE60236735D1
(de)
*
|
2001-04-13 |
2010-07-29 |
Biogen Idec Inc |
Antikörper gegen vla-1
|
AU2002315857B2
(en)
|
2001-06-22 |
2007-07-26 |
Kaisha, Chugai Seiyaku Kabushiki |
Cell proliferation inhibitors containing anti-glypican 3 antibody
|
MX342385B
(es)
|
2001-08-17 |
2016-09-27 |
Genentech Inc |
Inhibidores de la ruta del complemento que se unen a c5 y c5a sin evitar la formación de c5b.
|
US20030049203A1
(en)
|
2001-08-31 |
2003-03-13 |
Elmaleh David R. |
Targeted nucleic acid constructs and uses related thereto
|
US7320789B2
(en)
|
2001-09-26 |
2008-01-22 |
Wyeth |
Antibody inhibitors of GDF-8 and uses thereof
|
JP2005532253A
(ja)
|
2001-10-25 |
2005-10-27 |
ジェネンテック・インコーポレーテッド |
糖タンパク質組成物
|
US20030190705A1
(en)
|
2001-10-29 |
2003-10-09 |
Sunol Molecular Corporation |
Method of humanizing immune system molecules
|
DE10156482A1
(de)
|
2001-11-12 |
2003-05-28 |
Gundram Jung |
Bispezifisches Antikörper-Molekül
|
ATE395413T1
(de)
|
2001-12-03 |
2008-05-15 |
Amgen Fremont Inc |
Antikörperkategorisierung auf der grundlage von bindungseigenschaften
|
AU2002362197A1
(en)
|
2001-12-28 |
2003-07-24 |
Chugai Seiyaku Kabushiki Kaisha |
Method of stabilizing protein
|
ATE401390T1
(de)
*
|
2002-01-18 |
2008-08-15 |
Zymogenetics Inc |
Zytokin (zcytor17-ligand)
|
EP1576112B1
(en)
*
|
2002-01-18 |
2012-02-29 |
ZymoGenetics, Inc. |
Cytokine receptor zcytor17 multimers
|
BR0307548A
(pt)
*
|
2002-02-11 |
2006-01-17 |
Genentech Inc |
Método de produção de uma variante de anticorpo, variante de anticorpo, composição, ácido nucléico isolado, vetor, célula hospedeira, processo para a produção de uma variante de anticorpo e método de determinação do coeficiente de associação de antìgeno de um anticorpo
|
US7662925B2
(en)
|
2002-03-01 |
2010-02-16 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
AU2003217912A1
(en)
|
2002-03-01 |
2003-09-16 |
Xencor |
Antibody optimization
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
US8188231B2
(en)
*
|
2002-09-27 |
2012-05-29 |
Xencor, Inc. |
Optimized FC variants
|
WO2003087163A1
(fr)
|
2002-04-15 |
2003-10-23 |
Chugai Seiyaku Kabushiki Kaisha |
Procede d'elaboration d'une banque scdb
|
JP4518941B2
(ja)
|
2002-04-26 |
2010-08-04 |
中外製薬株式会社 |
アゴニスト抗体のスクリーニング方法
|
JP2004086862A
(ja)
|
2002-05-31 |
2004-03-18 |
Celestar Lexico-Sciences Inc |
タンパク質相互作用情報処理装置、タンパク質相互作用情報処理方法、プログラム、および、記録媒体
|
WO2003107218A1
(ja)
|
2002-05-31 |
2003-12-24 |
セレスター・レキシコ・サイエンシズ株式会社 |
相互作用予測装置
|
JP4468803B2
(ja)
|
2002-05-31 |
2010-05-26 |
ジーイー・ヘルスケア・バイオ−サイエンシーズ・アーベー |
結合剤を基板表面にカップリングさせる方法
|
CA2488836A1
(en)
|
2002-06-12 |
2003-12-24 |
Genencor International, Inc. |
Methods and compositions for milieu-dependent binding of a targeted agent to a target
|
ITMI20021527A1
(it)
|
2002-07-11 |
2004-01-12 |
Consiglio Nazionale Ricerche |
Anticorpi anti componente c5 del complemento e loro uso
|
EP1382969A1
(en)
|
2002-07-17 |
2004-01-21 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Diagnosis and prevention of cancer cell invasion
|
TW200407335A
(en)
*
|
2002-07-22 |
2004-05-16 |
Chugai Pharmaceutical Co Ltd |
Non-neutralizing antibody to inhibit the inactivation of activated protein C
|
WO2004016740A2
(en)
|
2002-08-15 |
2004-02-26 |
Epitomics, Inc. |
Humanized rabbit antibodies
|
WO2004024092A2
(en)
|
2002-09-16 |
2004-03-25 |
Wyeth |
Metalloprotease activation of myostatin, and methods of modulating myostatin activity
|
EP2345671B8
(en)
|
2002-09-27 |
2023-01-11 |
Xencor, Inc. |
Optimized fc variants and methods for their generation
|
US7217797B2
(en)
|
2002-10-15 |
2007-05-15 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
AU2003286467B2
(en)
|
2002-10-15 |
2009-10-01 |
Abbvie Biotherapeutics Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
GB0224082D0
(en)
|
2002-10-16 |
2002-11-27 |
Celltech R&D Ltd |
Biological products
|
US7261893B2
(en)
|
2002-10-22 |
2007-08-28 |
Wyeth |
Neutralizing antibodies against GDF-8 and uses therefor
|
US7282568B2
(en)
|
2002-12-16 |
2007-10-16 |
Medarex, Inc. |
Human monoclonal antibodies against interleukin 8 (IL-8)
|
SI2263692T1
(sl)
|
2002-12-24 |
2020-10-30 |
Rinat Neuroscience Corp. |
Anti-NGF protitelesa in postopki, v katerih se le-ta uporabljajo
|
WO2004060919A1
(ja)
|
2002-12-26 |
2004-07-22 |
Chugai Seiyaku Kabushiki Kaisha |
ヘテロ受容体に対するアゴニスト抗体
|
JP4477579B2
(ja)
|
2003-01-21 |
2010-06-09 |
中外製薬株式会社 |
抗体の軽鎖スクリーニング方法
|
JP2006517109A
(ja)
|
2003-02-07 |
2006-07-20 |
プロテイン デザイン ラブス インコーポレイテッド |
アンフィレグリン抗体ならびに癌および乾癬を処置するためのその使用
|
US20040223970A1
(en)
*
|
2003-02-28 |
2004-11-11 |
Daniel Afar |
Antibodies against SLC15A2 and uses thereof
|
US20040258705A1
(en)
|
2003-02-28 |
2004-12-23 |
Antigenics Inc. |
Use of lectins to promote oligomerization of glycoproteins and antigenic molecules
|
US8388955B2
(en)
|
2003-03-03 |
2013-03-05 |
Xencor, Inc. |
Fc variants
|
WO2004091543A2
(en)
|
2003-03-04 |
2004-10-28 |
Alexion Pharmaceuticals, Inc. |
Method of treating autoimmune disease by inducing antigen presentation by tolerance inducing antigen presenting cells
|
GB0306098D0
(en)
*
|
2003-03-18 |
2003-04-23 |
Platform Diagnostics Group Ltd |
Sample testing device
|
KR20110091598A
(ko)
|
2003-03-24 |
2011-08-11 |
지모제넥틱스, 인코포레이티드 |
항-il-22ra 항체 및 결합 파트너 및 염증에 있어서의 사용 방법
|
GB2400851B
(en)
|
2003-04-25 |
2004-12-15 |
Bioinvent Int Ab |
Identifying binding of a polypeptide to a polypeptide target
|
GB2401040A
(en)
|
2003-04-28 |
2004-11-03 |
Chugai Pharmaceutical Co Ltd |
Method for treating interleukin-6 related diseases
|
US9051373B2
(en)
|
2003-05-02 |
2015-06-09 |
Xencor, Inc. |
Optimized Fc variants
|
EP1639009B1
(en)
*
|
2003-05-30 |
2013-02-27 |
Merus B.V. |
Fab library for the preparation of a mixture of antibodies
|
EP1629010A1
(en)
|
2003-05-30 |
2006-03-01 |
Genentech, Inc. |
Treatment with anti-vegf antibodies
|
JP5110877B2
(ja)
|
2003-06-02 |
2012-12-26 |
ワイス・エルエルシー |
神経筋障害を処置するための、コルチコステロイドと組み合わせたミオスタチン(gdf8)インヒビターの使用
|
WO2005000351A2
(en)
|
2003-06-05 |
2005-01-06 |
Genentech, Inc. |
Combination therapy for b cell disorders
|
US8597911B2
(en)
|
2003-06-11 |
2013-12-03 |
Chugai Seiyaku Kabushiki Kaisha |
Process for producing antibodies
|
WO2004113387A2
(en)
|
2003-06-24 |
2004-12-29 |
Merck Patent Gmbh |
Tumour necrosis factor receptor molecules with reduced immunogenicity
|
US20050033029A1
(en)
|
2003-06-30 |
2005-02-10 |
Jin Lu |
Engineered anti-target immunoglobulin derived proteins, compositions, methods and uses
|
WO2005023193A2
(en)
|
2003-09-04 |
2005-03-17 |
Interleukin Genetics, Inc. |
Methods of treating endometriosis
|
US7297336B2
(en)
|
2003-09-12 |
2007-11-20 |
Baxter International Inc. |
Factor IXa specific antibodies displaying factor VIIIa like activity
|
JP2005101105A
(ja)
|
2003-09-22 |
2005-04-14 |
Canon Inc |
位置決め装置、露光装置、デバイス製造方法
|
US8101720B2
(en)
|
2004-10-21 |
2012-01-24 |
Xencor, Inc. |
Immunoglobulin insertions, deletions and substitutions
|
JP2005112514A
(ja)
|
2003-10-06 |
2005-04-28 |
Tadano Ltd |
伸縮ブーム
|
WO2005035753A1
(ja)
|
2003-10-10 |
2005-04-21 |
Chugai Seiyaku Kabushiki Kaisha |
機能蛋白質を代替する二重特異性抗体
|
US20080075712A1
(en)
*
|
2003-10-14 |
2008-03-27 |
Kunihiro Hattori |
Double Specific Antibodies Substituting For Functional Proteins
|
EP1673395A1
(en)
|
2003-10-15 |
2006-06-28 |
PDL BioPharma, Inc. |
Alteration of fc-fusion protein serum half-lives by mutagenesis of positions 250, 314 and/or 428 of the heavy chain constant region of ig
|
RU2392967C2
(ru)
|
2003-10-17 |
2010-06-27 |
Тугаи Сейяку Кабусики Кайся |
Терапевтический агент для мезотелиомы
|
EP2385069A3
(en)
|
2003-11-12 |
2012-05-30 |
Biogen Idec MA Inc. |
Neonatal Fc rReceptor (FcRn)- binding polypeptide variants, dimeric Fc binding proteins and methods related thereto
|
US20050100965A1
(en)
|
2003-11-12 |
2005-05-12 |
Tariq Ghayur |
IL-18 binding proteins
|
US20050142133A1
(en)
*
|
2003-12-03 |
2005-06-30 |
Xencor, Inc. |
Optimized proteins that target the epidermal growth factor receptor
|
EP1697741A4
(en)
|
2003-12-04 |
2008-02-13 |
Xencor Inc |
PROCESS FOR PRODUCING PROTEIN VARIANTS WITH INCREASED HOST STRUCTURE CONTENT AND COMPOSITIONS THEREOF
|
HUE025328T2
(en)
*
|
2003-12-10 |
2016-03-29 |
Squibb & Sons Llc |
IP-10 antibodies and their use
|
HUE035520T2
(en)
|
2003-12-10 |
2018-05-28 |
Squibb & Sons Llc |
Interferon alpha antibodies and their use
|
AR048210A1
(es)
|
2003-12-19 |
2006-04-12 |
Chugai Pharmaceutical Co Ltd |
Un agente preventivo para la vasculitis.
|
EP1697520A2
(en)
|
2003-12-22 |
2006-09-06 |
Xencor, Inc. |
Fc polypeptides with novel fc ligand binding sites
|
AU2004308439A1
(en)
|
2003-12-22 |
2005-07-14 |
Centocor, Inc. |
Methods for generating multimeric molecules
|
WO2005063981A1
(ja)
|
2003-12-25 |
2005-07-14 |
Kirin Beer Kabushiki Kaisha |
抗cd40抗体の変異体
|
US20050266425A1
(en)
*
|
2003-12-31 |
2005-12-01 |
Vaccinex, Inc. |
Methods for producing and identifying multispecific antibodies
|
UA93855C2
(ru)
|
2003-12-31 |
2011-03-25 |
Шеринг-Плау Лтд. |
Вакцина, способствует росту, базирующейся ha нейтрализующем эпитопе
|
ITMI20040003A1
(it)
|
2004-01-07 |
2004-04-07 |
Zambon Spa |
Processo per la preparazione di 6-fluoro-2-metil-1-indanone
|
NZ548702A
(en)
|
2004-01-09 |
2009-06-26 |
Pfizer |
Antibodies to MAdCAM
|
EP1706424B1
(en)
|
2004-01-12 |
2009-07-22 |
Applied Molecular Evolution, Inc. |
Fc region variants
|
US20070116710A1
(en)
|
2004-02-03 |
2007-05-24 |
Leonard Bell |
Methods of treating hemolytic anemia
|
US20050169921A1
(en)
|
2004-02-03 |
2005-08-04 |
Leonard Bell |
Method of treating hemolytic disease
|
EP1715891B2
(en)
|
2004-02-11 |
2014-08-13 |
Warner-Lambert Company LLC |
Methods of treating osteoarthritis with anti-il-6 antibodies
|
BRPI0508716A
(pt)
|
2004-03-23 |
2007-08-07 |
Lilly Co Eli |
anticorpo monoclonal, processo para produzir o mesmo, composição farmacêutica, e, uso de um anticorpo monoclonal
|
KR20070035482A
(ko)
|
2004-03-24 |
2007-03-30 |
추가이 세이야쿠 가부시키가이샤 |
인터로킨-6 안타고니스트를 활성성분으로 함유하는내이장해 치료제
|
AR048335A1
(es)
|
2004-03-24 |
2006-04-19 |
Chugai Pharmaceutical Co Ltd |
Agentes terapeuticos para trastornos del oido interno que contienen un antagonista de il- 6 como un ingrediente activo
|
WO2005090405A1
(ja)
|
2004-03-24 |
2005-09-29 |
Chugai Seiyaku Kabushiki Kaisha |
インターロイキン-6受容体に対するヒト型化抗体のサブタイプ
|
EP1737890A2
(en)
|
2004-03-24 |
2007-01-03 |
Xencor, Inc. |
Immunoglobulin variants outside the fc region
|
US8435517B2
(en)
|
2008-09-17 |
2013-05-07 |
Xencor, Inc. |
Compositions and methods for treating IgE-mediated disorders
|
WO2005123780A2
(en)
|
2004-04-09 |
2005-12-29 |
Protein Design Labs, Inc. |
Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
|
WO2005112564A2
(en)
|
2004-04-15 |
2005-12-01 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Germline and sequence variants of humanized antibodies and methods of making and using them
|
WO2005115452A2
(en)
|
2004-04-16 |
2005-12-08 |
Macrogenics, Inc. |
Fcϝriib-specific antibodies and methods of use thereof
|
KR100620554B1
(ko)
|
2004-06-05 |
2006-09-06 |
한국생명공학연구원 |
Tag-72에 대한 인간화 항체
|
AR049390A1
(es)
|
2004-06-09 |
2006-07-26 |
Wyeth Corp |
Anticuerpos contra la interleuquina-13 humana y usos de los mismos
|
EP1773391A4
(en)
|
2004-06-25 |
2009-01-21 |
Medimmune Inc |
INCREASING THE PRODUCTION OF RECOMBINANT ANTIBODIES IN MAMMALIAN CELLS BY MUTAGENESIS ON THE SITE
|
WO2006023144A2
(en)
|
2004-07-06 |
2006-03-02 |
Bioren Inc. |
Look-through mutagenesis for developing altered polypeptides with enhanced properties
|
CN111925445A
(zh)
|
2004-07-09 |
2020-11-13 |
中外制药株式会社 |
抗-磷脂酰肌醇蛋白聚糖3抗体
|
WO2006085967A2
(en)
|
2004-07-09 |
2006-08-17 |
Xencor, Inc. |
OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS
|
EP2940043A1
(en)
|
2004-07-15 |
2015-11-04 |
Xencor, Inc. |
Optimized fc variants
|
CN101001873B
(zh)
|
2004-08-04 |
2013-03-13 |
曼璀克生物科技有限责任公司 |
Fc区变体
|
AU2005277567A1
(en)
|
2004-08-16 |
2006-03-02 |
Medimmune, Llc |
Integrin antagonists with enhanced antibody dependent cell-mediated cytotoxicity activity
|
KR20070057839A
(ko)
|
2004-08-19 |
2007-06-07 |
제넨테크, 인크. |
변경된 이펙터 기능을 갖는 폴리펩티드 변이체
|
AU2005282700A1
(en)
*
|
2004-09-02 |
2006-03-16 |
Genentech, Inc. |
Heteromultimeric molecules
|
US7572456B2
(en)
|
2004-09-13 |
2009-08-11 |
Macrogenics, Inc. |
Humanized antibodies against West Nile Virus and therapeutic and prophylactic uses thereof
|
US20080233131A1
(en)
|
2004-09-14 |
2008-09-25 |
Richard John Stebbings |
Vaccine
|
US20060074225A1
(en)
|
2004-09-14 |
2006-04-06 |
Xencor, Inc. |
Monomeric immunoglobulin Fc domains
|
TWI380996B
(zh)
|
2004-09-17 |
2013-01-01 |
Hoffmann La Roche |
抗ox40l抗體
|
US7563443B2
(en)
|
2004-09-17 |
2009-07-21 |
Domantis Limited |
Monovalent anti-CD40L antibody polypeptides and compositions thereof
|
CA2580981C
(en)
|
2004-09-22 |
2013-10-22 |
Kirin Beer Kabushiki Kaisha |
Stabilized human igg4 antibodies
|
WO2006047350A2
(en)
|
2004-10-21 |
2006-05-04 |
Xencor, Inc. |
IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
|
CN102731654A
(zh)
|
2004-10-22 |
2012-10-17 |
米迪缪尼有限公司 |
抗hmgb1的高亲和力抗体及其用法
|
US7928205B2
(en)
|
2004-10-22 |
2011-04-19 |
Amgen Inc. |
Methods for refolding of recombinant antibodies
|
CA2585891A1
(en)
|
2004-10-29 |
2006-05-11 |
Medimmune, Inc. |
Methods of preventing and treating rsv infections and related conditions
|
US7462697B2
(en)
|
2004-11-08 |
2008-12-09 |
Epitomics, Inc. |
Methods for antibody engineering
|
WO2007024249A2
(en)
|
2004-11-10 |
2007-03-01 |
Macrogenics, Inc. |
Engineering fc antibody regions to confer effector function
|
KR101027427B1
(ko)
|
2004-11-12 |
2011-04-11 |
젠코어 인코포레이티드 |
FcRn에 대하여 증가된 결합력을 갖는 Fc 변이체
|
US8367805B2
(en)
|
2004-11-12 |
2013-02-05 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
US8802820B2
(en)
|
2004-11-12 |
2014-08-12 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
CN101098890B
(zh)
|
2004-11-12 |
2012-07-18 |
赞科股份有限公司 |
对FcRn的结合被改变的Fc变体
|
JP5787461B2
(ja)
|
2004-12-14 |
2015-09-30 |
ジーイー・ヘルスケア・バイオサイエンス・アクチボラグ |
免疫グロブリンの精製方法
|
US8329186B2
(en)
|
2004-12-20 |
2012-12-11 |
Isu Abxis Co., Ltd |
Treatment of inflammation using BST2 inhibitor
|
US20090061485A1
(en)
|
2004-12-22 |
2009-03-05 |
Chugai Seiyaku Kabushiki Kaisha |
Method of Producing an Antibody Using a Cell in Which the Function of Fucose Transporter Is Inhibited
|
US8728828B2
(en)
|
2004-12-22 |
2014-05-20 |
Ge Healthcare Bio-Sciences Ab |
Purification of immunoglobulins
|
AU2005321974B2
(en)
|
2004-12-27 |
2011-11-17 |
Progenics Pharmaceuticals (Nevada), Inc. |
Orally deliverable and anti-toxin antibodies and methods for making and using them
|
RU2481356C2
(ru)
|
2004-12-28 |
2013-05-10 |
Иннейт Фарма |
Моноклональные антитела против nkg2a
|
JP4986633B2
(ja)
|
2005-01-12 |
2012-07-25 |
協和発酵キリン株式会社 |
安定化されたヒトIgG2およびIgG3抗体
|
WO2006076594A2
(en)
*
|
2005-01-12 |
2006-07-20 |
Xencor, Inc. |
Antibodies and fc fusion proteins with altered immunogenicity
|
NZ538097A
(en)
|
2005-02-07 |
2006-07-28 |
Ovita Ltd |
Method and compositions for improving wound healing
|
JP2008530132A
(ja)
*
|
2005-02-14 |
2008-08-07 |
ザイモジェネティクス, インコーポレイテッド |
Il−31raアンタゴニストを用いて皮膚障害を治療する方法
|
US20060263357A1
(en)
|
2005-05-05 |
2006-11-23 |
Tedder Thomas F |
Anti-CD19 antibody therapy for autoimmune disease
|
EP1869192B1
(en)
|
2005-03-18 |
2016-01-20 |
MedImmune, LLC |
Framework-shuffling of antibodies
|
US9493569B2
(en)
|
2005-03-31 |
2016-11-15 |
Chugai Seiyaku Kabushiki Kaisha |
Structural isomers of sc(Fv)2
|
CA2602663A1
(en)
|
2005-03-31 |
2006-10-05 |
Xencor, Inc. |
Fc variants with optimized properties
|
ES2592271T3
(es)
|
2005-03-31 |
2016-11-29 |
Chugai Seiyaku Kabushiki Kaisha |
Métodos de producción de polipéptidos mediante la regulación de la asociación de los polipéptidos
|
TW200714313A
(en)
|
2005-04-08 |
2007-04-16 |
Chugai Pharmaceutical Co Ltd |
Antibodies that substitute for coagulation factor VIII
|
NZ561704A
(en)
|
2005-04-15 |
2009-10-30 |
Genentech Inc |
HGF beta chain variants
|
EP1874820A4
(en)
|
2005-04-20 |
2010-09-22 |
Amgen Fremont Inc |
HIGH AFFINE, COMPLETELY HUMAN MONOCLONAL ANTIBODY AGAINST INTERLEUKIN-8 AND EPITOPES FOR SUCH ANTIBODIES
|
WO2006116269A2
(en)
|
2005-04-25 |
2006-11-02 |
Pfizer Inc. |
Antibodies to myostatin
|
AU2006239851B2
(en)
|
2005-04-26 |
2011-06-16 |
Medimmune, Llc |
Modulation of antibody effector function by hinge domain engineering
|
JO3058B1
(ar)
|
2005-04-29 |
2017-03-15 |
Applied Molecular Evolution Inc |
الاجسام المضادة لمضادات -اي ال-6,تركيباتها طرقها واستعمالاتها
|
UY29504A1
(es)
|
2005-04-29 |
2006-10-31 |
Rinat Neuroscience Corp |
Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos.
|
US8003108B2
(en)
|
2005-05-03 |
2011-08-23 |
Amgen Inc. |
Sclerostin epitopes
|
ES2523666T3
(es)
|
2005-05-31 |
2014-11-28 |
Board Of Regents, The University Of Texas System |
Anticuerpos IgG1 con la parte Fc mutada para el aumento de unión al receptor FcRn y usos de los mismos
|
EP1908482B1
(en)
*
|
2005-06-10 |
2017-09-06 |
Chugai Seiyaku Kabushiki Kaisha |
Stabilizer for protein preparation comprising meglumine and use thereof
|
TW200718780A
(en)
|
2005-06-10 |
2007-05-16 |
Chugai Pharmaceutical Co Ltd |
Sc(Fv)2 site-directed mutant
|
CA2613512A1
(en)
|
2005-06-23 |
2007-01-04 |
Medimmune, Inc. |
Antibody formulations having optimized aggregation and fragmentation profiles
|
CA2652434A1
(en)
|
2005-07-08 |
2007-01-18 |
Xencor, Inc. |
Optimized proteins that target ep-cam
|
US20070036786A1
(en)
|
2005-07-11 |
2007-02-15 |
Nadine Tuaillon |
Method of treating autoimmune disease using humanized anti-CD16A antibodies
|
PT1919503E
(pt)
|
2005-08-10 |
2015-01-05 |
Macrogenics Inc |
Identificação e manipulação de anticorpos com a regiões de fc variantes e métodos de utilização dos mesmos
|
WO2007024535A2
(en)
|
2005-08-19 |
2007-03-01 |
Wyeth |
Antagonist antibodies against gdf-8 and uses in treatment of als and other gdf-8-associated disorders
|
EP1789435B1
(en)
|
2005-09-12 |
2010-02-24 |
Industry Foundation of Chonnam National University |
A method for production of mature natural killer cell
|
CA2622772A1
(en)
|
2005-09-29 |
2007-04-12 |
Viral Logic Systems Technology Corp. |
Immunomodulatory compositions and uses therefor
|
CA2624189A1
(en)
|
2005-10-03 |
2007-04-12 |
Xencor, Inc. |
Fc variants with optimized fc receptor binding properties
|
WO2007044411A2
(en)
|
2005-10-06 |
2007-04-19 |
Eli Lilly And Company |
Anti-myostatin antibodies
|
JP4860703B2
(ja)
|
2005-10-06 |
2012-01-25 |
ゼンコー・インコーポレイテッド |
最適化された抗cd30抗体
|
UA92504C2
(xx)
|
2005-10-12 |
2010-11-10 |
Эли Лилли Энд Компани |
Антиміостатинове моноклональне антитіло$антимиостатиновое моноклональное антитело
|
CA2625773C
(en)
|
2005-10-14 |
2015-05-12 |
Fukuoka University |
Inhibition of interleukin-6 (il-6) receptor promotes pancreatic islet transplantation
|
US8945558B2
(en)
|
2005-10-21 |
2015-02-03 |
Chugai Seiyaku Kabushiki Kaisha |
Methods for treating myocardial infarction comprising administering an IL-6 inhibitor
|
AR057582A1
(es)
|
2005-11-15 |
2007-12-05 |
Nat Hospital Organization |
Agentes para suprimir la induccion de linfocitos t citotoxicos
|
WO2007060411A1
(en)
|
2005-11-24 |
2007-05-31 |
Ucb Pharma S.A. |
Anti-tnf alpha antibodies which selectively inhibit tnf alpha signalling through the p55r
|
AR057941A1
(es)
|
2005-11-25 |
2007-12-26 |
Univ Keio |
Agentes terapeuticos para el cancer de prostata
|
AU2006330807A1
(en)
|
2005-11-28 |
2007-07-05 |
Medimmune, Llc |
Antagonists of HMBG1 and/or rage and methods of use thereof
|
BRPI0619747B8
(pt)
|
2005-12-12 |
2021-05-25 |
Ac Immune Sa |
método para produzir uma composição de vacina terapêutica, construto antigênico, composição de vacina, usos de um construto antigênico, e, método para preparar e produzir um medicamento para o tratamento de uma condição ou doença associada com amilóide
|
EP1977763A4
(en)
|
2005-12-28 |
2010-06-02 |
Chugai Pharmaceutical Co Ltd |
STABILIZER PREPARATION CONTAINING ANTIBODIES
|
WO2007133816A2
(en)
*
|
2006-01-10 |
2007-11-22 |
Zymogenetics, Inc. |
Methods of treating pain and inflammation in neuronal tissue using il-31ra and osmrb antagonists
|
NZ569903A
(en)
*
|
2006-01-12 |
2012-07-27 |
Alexion Pharma Inc |
Antibodies to OX-2/CD200 and uses thereof
|
AR059213A1
(es)
|
2006-01-27 |
2008-03-19 |
Univ Keio |
Agentes terapeuticos para enfermedades que involucran neovascularizacion coroidal
|
EP1988922A4
(en)
|
2006-02-03 |
2010-06-02 |
Medimmune Llc |
PROTEIN FORMULATIONS
|
US20070190056A1
(en)
|
2006-02-07 |
2007-08-16 |
Ravi Kambadur |
Muscle regeneration compositions and uses therefor
|
EP1988882B1
(en)
|
2006-03-02 |
2014-12-17 |
Alexion Pharmaceuticals, Inc. |
Prolongation of survival of an allograft by inhibiting complement activity
|
EP4159220A1
(en)
|
2006-03-08 |
2023-04-05 |
Archemix LLC |
Complement binding aptamers and anti-c5 agents useful in the treatment of ocular disorders
|
EP3167888B1
(en)
|
2006-03-15 |
2024-05-01 |
Alexion Pharmaceuticals, Inc. |
Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
|
TW200808347A
(en)
|
2006-03-23 |
2008-02-16 |
Kirin Brewery |
Agonistic antibody directed against human thrombopoietin receptor
|
AU2007227813B2
(en)
|
2006-03-23 |
2012-09-27 |
Bioarctic Neuroscience Ab |
Improved protofibril selective antibodies and the use thereof
|
JP2009532027A
(ja)
|
2006-03-28 |
2009-09-10 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
抗igf−1r抗体およびその使用
|
US9670269B2
(en)
|
2006-03-31 |
2017-06-06 |
Chugai Seiyaku Kabushiki Kaisha |
Methods of modifying antibodies for purification of bispecific antibodies
|
DK3056568T3
(da)
|
2006-03-31 |
2021-11-01 |
Chugai Pharmaceutical Co Ltd |
Fremgangsmåder til kontrollering af antistoffers blodfarmakokinetik
|
JP5754875B2
(ja)
|
2006-04-07 |
2015-07-29 |
国立大学法人大阪大学 |
筋再生促進剤
|
TWI395754B
(zh)
|
2006-04-24 |
2013-05-11 |
Amgen Inc |
人類化之c-kit抗體
|
CA2652733C
(en)
|
2006-05-25 |
2016-06-21 |
Glaxo Group Limited |
Modified humanised anti-interleukin-18 antibodies
|
CN102585002A
(zh)
|
2006-06-02 |
2012-07-18 |
瑞泽恩制药公司 |
人il-6受体的高亲和力抗体
|
US8080248B2
(en)
|
2006-06-02 |
2011-12-20 |
Regeneron Pharmaceuticals, Inc. |
Method of treating rheumatoid arthritis with an IL-6R antibody
|
EP2047863B1
(en)
|
2006-06-08 |
2013-07-31 |
Chugai Seiyaku Kabushiki Kaisha |
Preventive or remedy for inflammatory disease
|
US7858756B2
(en)
*
|
2006-06-15 |
2010-12-28 |
The Board Of Trustees Of The University Of Arkansas |
Monoclonal antibodies that selectively recognize methamphetamine and methamphetamine like compounds
|
EP2035456A1
(en)
|
2006-06-22 |
2009-03-18 |
Novo Nordisk A/S |
Production of bispecific antibodies
|
TW200817006A
(en)
|
2006-06-23 |
2008-04-16 |
Smithkline Beecham Corp |
IL-8 receptor antagonist
|
ES2402591T3
(es)
|
2006-08-14 |
2013-05-07 |
Xencor Inc. |
Anticuerpos optimizados que seleccionan como diana CD19
|
US8063188B2
(en)
|
2006-09-05 |
2011-11-22 |
Eli Lilly And Company |
Anti-myostatin antibodies
|
ES2383710T3
(es)
|
2006-09-08 |
2012-06-25 |
Medimmune, Llc |
Anticuerpos anti-CD19 humanizados y su uso en el tratamiento de tumores, trasplantes y enfermedades autoinmunes
|
EP2064240A2
(en)
|
2006-09-18 |
2009-06-03 |
Xencor, Inc. |
Optimized antibodies that target hm1.24
|
US20100034194A1
(en)
|
2006-10-11 |
2010-02-11 |
Siemens Communications Inc. |
Eliminating unreachable subscribers in voice-over-ip networks
|
WO2008121160A2
(en)
|
2006-11-21 |
2008-10-09 |
Xencor, Inc. |
Optimized antibodies that target cd5
|
WO2008091798A2
(en)
|
2007-01-22 |
2008-07-31 |
Xencor, Inc. |
Optimized ca9 antibodies and methods of using the same
|
CN101646459B
(zh)
|
2007-01-23 |
2014-02-12 |
国立大学法人信州大学 |
慢性排斥反应抑制剂
|
JP5357778B2
(ja)
|
2007-01-23 |
2013-12-04 |
ゼンコー・インコーポレイテッド |
最適化cd40抗体および前記を使用する方法
|
WO2008090960A1
(ja)
|
2007-01-24 |
2008-07-31 |
Kyowa Hakko Kirin Co., Ltd. |
ガングリオシドgm2に特異的に結合する遺伝子組換え抗体組成物
|
WO2008092117A2
(en)
|
2007-01-25 |
2008-07-31 |
Xencor, Inc. |
Immunoglobulins with modifications in the fcr binding region
|
WO2008098115A2
(en)
|
2007-02-07 |
2008-08-14 |
Xencor, Inc. |
Optimized igf-1r antibodies and methods of using the same
|
US7919594B2
(en)
*
|
2007-02-14 |
2011-04-05 |
Vaccinex, Inc. |
Human anti-CD100 antibodies
|
MX2009009079A
(es)
|
2007-02-23 |
2009-08-31 |
Schering Corp |
Anticuerpos anti-il-23p19 de ingenieria.
|
EP2138576A4
(en)
|
2007-03-16 |
2011-02-23 |
Kyowa Hakko Kirin Co Ltd |
ANTI-CLAUDIN-4 ANTIBODY
|
WO2008113834A2
(en)
|
2007-03-22 |
2008-09-25 |
Novartis Ag |
C5 antigens and uses thereof
|
EP2132312B1
(en)
|
2007-03-27 |
2016-01-27 |
Sea Lane Biotechnologies,llc. |
Constructs and libraries comprising antibody surrogate light chain sequences
|
EP2139924B1
(en)
|
2007-03-29 |
2016-07-06 |
Genmab A/S |
Bispecific antibodies and methods for production thereof
|
CL2008001071A1
(es)
|
2007-04-17 |
2009-05-22 |
Smithkline Beecham Corp |
Metodo para obtener anticuerpo penta-especifico contra il-8/cxcl8, gro-alfa/cxcl1, gro-beta/cxcl2), gro-gama/cxcl3 y ena-78/cxcl5 humanas; anticuerpo penta-especifico; proceso de produccion del mismo; vector, hbridoma o celela que lo comprende; composicion farmceutica; uso para tratar copd, otras enfermedades.
|
GB0708002D0
(en)
|
2007-04-25 |
2007-06-06 |
Univ Sheffield |
Antibodies
|
BRPI0811857A2
(pt)
|
2007-05-14 |
2014-10-21 |
Biogen Idec Inc |
Regiões fc (scfc) de cadeia simples, polipeptídeos de aglutinação que as compreendem e métodos relacionados.
|
LT2176298T
(lt)
*
|
2007-05-30 |
2018-04-10 |
Xencor, Inc. |
Būdai ir kompozicijos, skirti cd32b ekspresuojančių ląstelių slopinimui
|
WO2008145141A1
(en)
|
2007-05-31 |
2008-12-04 |
Genmab A/S |
Method for extending the half-life of exogenous or endogenous soluble molecules
|
AU2008255352B2
(en)
|
2007-05-31 |
2014-05-22 |
Genmab A/S |
Stable IgG4 antibodies
|
CN101849001B
(zh)
|
2007-06-25 |
2014-07-16 |
艾斯巴技术-诺华有限责任公司 |
修饰抗体的方法和具有改善的功能性质的修饰抗体
|
PL2164961T3
(pl)
|
2007-06-25 |
2015-08-31 |
Esbatech Alcon Biomed Res Unit |
Oparta na sekwencjach inżynieria i optymalizacja przeciwciał jednołańcuchowych
|
RS54624B1
(en)
|
2007-07-17 |
2016-08-31 |
E. R. Squibb & Sons, L.L.C. |
MONOCLONIC ANTIBODIES AGAINST GLIPICAN-3
|
JP5424330B2
(ja)
|
2007-07-26 |
2014-02-26 |
国立大学法人大阪大学 |
インターロイキン6受容体阻害剤を有効成分とする眼炎症疾患治療剤
|
WO2009026117A2
(en)
|
2007-08-16 |
2009-02-26 |
Glaxo Group Limited |
Novel compounds
|
JP2010538012A
(ja)
|
2007-08-28 |
2010-12-09 |
バイオジェン アイデック マサチューセッツ インコーポレイテッド |
Igf−1rの複数のエピトープに結合する組成物
|
US20090092614A1
(en)
|
2007-08-28 |
2009-04-09 |
Biogen Idec Ma Inc. |
Anti-IGF-1R Antibodies and Uses Thereof
|
EP2031064A1
(de)
*
|
2007-08-29 |
2009-03-04 |
Boehringer Ingelheim Pharma GmbH & Co. KG |
Verfahren zur Steigerung von Proteintitern
|
EP2197911A2
(en)
|
2007-09-14 |
2010-06-23 |
Amgen Inc. |
Homogeneous antibody populations
|
CN101874042B9
(zh)
|
2007-09-26 |
2019-01-01 |
中外制药株式会社 |
利用cdr的氨基酸取代来改变抗体等电点的方法
|
KR101561314B1
(ko)
|
2007-09-26 |
2015-10-16 |
추가이 세이야쿠 가부시키가이샤 |
항il-6 수용체 항체
|
CN101874041B
(zh)
|
2007-09-26 |
2013-06-19 |
中外制药株式会社 |
抗体恒定区修饰体
|
WO2009041734A1
(ja)
|
2007-09-26 |
2009-04-02 |
Kyowa Hakko Kirin Co., Ltd. |
ヒトトロンボポエチン受容体に対するアゴニスト抗体
|
NZ584769A
(en)
|
2007-09-28 |
2011-09-30 |
Chugai Pharmaceutical Co Ltd |
Anti-glypican-3 antibody having improved kinetics in plasma
|
MX2010003139A
(es)
|
2007-10-02 |
2010-04-07 |
Chugai Pharmaceutical Co Ltd |
Agentes terapeuticos para la enfermedad de injerto contra hospedero que comprenden un inhibidor del receptor de interleucina 6 como ingrediente activo.
|
JO3076B1
(ar)
|
2007-10-17 |
2017-03-15 |
Janssen Alzheimer Immunotherap |
نظم العلاج المناعي المعتمد على حالة apoe
|
WO2009053358A1
(en)
|
2007-10-22 |
2009-04-30 |
Merck Serono S.A. |
Method for purifying fc-fusion proteins
|
JP5314033B2
(ja)
|
2007-10-22 |
2013-10-16 |
メルク セローノ ソシエテ アノニム |
突然変異IgGFcフラグメントと融合した単一IFN−ベータ
|
AU2008345242B2
(en)
|
2007-10-31 |
2014-02-27 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
PE20091163A1
(es)
|
2007-11-01 |
2009-08-09 |
Wyeth Corp |
Anticuerpos para gdf8
|
US9175091B2
(en)
|
2007-11-15 |
2015-11-03 |
Chugai Seiyaku Kabushiki Kaisha |
Monoclonal antibody capable of binding to anexelekto, and use thereof
|
ES2585480T3
(es)
*
|
2007-12-05 |
2016-10-06 |
Chugai Seiyaku Kabushiki Kaisha |
Anticuerpo anti-NR10 y uso del mismo
|
CN104162155A
(zh)
|
2007-12-05 |
2014-11-26 |
中外制药株式会社 |
搔痒症治疗药
|
ES2550757T3
(es)
|
2007-12-18 |
2015-11-12 |
Bioalliance C.V. |
Anticuerpos que reconocen un epítopo que contiene carbohidratos en CD43 y ACE expresados en células cancerosas y métodos de uso de los mismos
|
PE20091174A1
(es)
|
2007-12-27 |
2009-08-03 |
Chugai Pharmaceutical Co Ltd |
Formulacion liquida con contenido de alta concentracion de anticuerpo
|
JP6157046B2
(ja)
|
2008-01-07 |
2017-07-05 |
アムジェン インコーポレイテッド |
静電的ステアリング(electrostaticsteering)効果を用いた抗体Fcヘテロ二量体分子を作製するための方法
|
DK2229409T3
(da)
|
2008-01-18 |
2013-01-14 |
Sanquin Bloedvoorziening |
Fremgangsmåde til at forøge den terapeutiske effektivitet af immunoglobulin-G-klasse-3-(IgG3)-antistoffer
|
CN101932593B
(zh)
|
2008-01-29 |
2014-08-20 |
埃博灵克斯股份有限公司 |
稳定蛋白和多肽的方法
|
DK2250279T3
(en)
|
2008-02-08 |
2016-08-01 |
Medimmune Llc |
ANTI-IFNAR1 antibodies with reduced Fc ligand affinity-
|
AU2015227424A1
(en)
|
2008-04-11 |
2015-10-01 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
|
DK2275443T3
(en)
|
2008-04-11 |
2016-02-08 |
Chugai Pharmaceutical Co Ltd |
Antigen-binding molecule capable of repetitively binding to two or more antigen molecules
|
US9315577B2
(en)
|
2008-05-01 |
2016-04-19 |
Amgen Inc. |
Anti-hepcidin antibodies and methods of use
|
JP5646459B2
(ja)
|
2008-05-14 |
2014-12-24 |
アグリカルチャー ヴィクトリア サービス ピーティーワイ エルティーディーAgriculture Victoria Services Pty Ltd |
疾患及び障害を治療するためのアンギオゲニン又はアンギオゲニンアゴニストの使用
|
KR101665729B1
(ko)
|
2008-06-05 |
2016-10-12 |
국립연구개발법인 고쿠리츠간켄큐센터 |
신경침윤 억제제
|
CN102170906B
(zh)
|
2008-08-05 |
2014-07-30 |
诺华股份有限公司 |
靶定补体蛋白c5的抗体的组合物和方法
|
JP5028372B2
(ja)
|
2008-09-26 |
2012-09-19 |
京セラドキュメントソリューションズ株式会社 |
画像処理装置、画像処理方法及び画像処理プログラム
|
TWI440469B
(zh)
|
2008-09-26 |
2014-06-11 |
Chugai Pharmaceutical Co Ltd |
Improved antibody molecules
|
CN102292352A
(zh)
|
2008-10-10 |
2011-12-21 |
新兴产品开发西雅图有限公司 |
Tcr复合物免疫治疗剂
|
MX2011004001A
(es)
|
2008-10-14 |
2011-05-19 |
Genentech Inc |
Variantes de inmunoglobulinas y sus usos.
|
KR20110094029A
(ko)
|
2008-11-10 |
2011-08-19 |
알렉시온 파마슈티칼스, 인코포레이티드 |
보체-관련된 장애를 치료하는 방법 및 조성물
|
JP5807300B2
(ja)
|
2008-11-18 |
2015-11-10 |
株式会社シノテスト |
試料中のc反応性蛋白質の測定方法及び測定試薬
|
BRPI0921569A2
(pt)
|
2008-11-25 |
2019-09-24 |
Alder Biopharmaceuticals Inc |
anticorpos para il-6 e uso dos mesmos
|
WO2010064090A1
(en)
|
2008-12-02 |
2010-06-10 |
Pierre Fabre Medicament |
Process for the modulation of the antagonistic activity of a monoclonal antibody
|
AR074438A1
(es)
|
2008-12-02 |
2011-01-19 |
Pf Medicament |
Proceso para la modulacion de la actividad antagonista de un anticuerpo monoclonal
|
KR20160062207A
(ko)
|
2008-12-05 |
2016-06-01 |
추가이 세이야쿠 가부시키가이샤 |
항nr10 항체 및 그의 이용
|
AR074777A1
(es)
|
2008-12-19 |
2011-02-09 |
Glaxo Group Ltd |
Proteinas de union a antigeno
|
CN102482347B
(zh)
|
2009-01-12 |
2017-04-26 |
希托马克斯医疗有限责任公司 |
修饰抗体组合物及其制备和使用方法
|
CA2750533A1
(en)
|
2009-01-23 |
2010-07-29 |
Biogen Idec Ma Inc. |
Stabilized fc polypeptides with reduced effector function and methods of use
|
JP2010210772A
(ja)
|
2009-03-13 |
2010-09-24 |
Dainippon Screen Mfg Co Ltd |
液晶表示装置の製造方法
|
US9228017B2
(en)
*
|
2009-03-19 |
2016-01-05 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody constant region variant
|
US20120071634A1
(en)
*
|
2009-03-19 |
2012-03-22 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody Constant Region Variant
|
SG10201900451SA
(en)
|
2009-03-19 |
2019-02-27 |
Chugai Pharmaceutical Co Ltd |
Pharmaceutical formulation containing improved antibody molecules
|
EP2233500A1
(en)
|
2009-03-20 |
2010-09-29 |
LFB Biotechnologies |
Optimized Fc variants
|
JP5616428B2
(ja)
|
2009-04-07 |
2014-10-29 |
ロシュ グリクアート アクチェンゲゼルシャフト |
三価の二重特異性抗体
|
AU2010201495B2
(en)
|
2009-04-16 |
2012-04-12 |
Accenture Global Services Limited |
Touchpoint customization system
|
EP3505636A1
(en)
|
2009-04-27 |
2019-07-03 |
OncoMed Pharmaceuticals, Inc. |
Method for making heteromultimeric molecules
|
CN102459344A
(zh)
|
2009-05-15 |
2012-05-16 |
中外制药株式会社 |
抗axl抗体
|
US8609097B2
(en)
|
2009-06-10 |
2013-12-17 |
Hoffmann-La Roche Inc. |
Use of an anti-Tau pS422 antibody for the treatment of brain diseases
|
JP2012531418A
(ja)
|
2009-06-23 |
2012-12-10 |
アレクシオン ファーマシューティカルズ, インコーポレイテッド |
補体タンパク質に結合する二重特異性抗体
|
US8945511B2
(en)
|
2009-06-25 |
2015-02-03 |
Paul Weinberger |
Sensitive methods for detecting the presence of cancer associated with the over-expression of galectin-3 using biomarkers derived from galectin-3
|
KR20120027055A
(ko)
|
2009-06-26 |
2012-03-20 |
리제네론 파라마큐티칼스 인코포레이티드 |
천연 면역글로불린 포맷을 가지는 용이하게 분리된 이중특이성 항체
|
GB0914691D0
(en)
|
2009-08-21 |
2009-09-30 |
Lonza Biologics Plc |
Immunoglobulin variants
|
CA2771575A1
(en)
|
2009-08-29 |
2011-03-03 |
Abbott Laboratories |
Therapeutic dll4 binding proteins
|
EP3023438B1
(en)
|
2009-09-03 |
2020-03-11 |
Merck Sharp & Dohme Corp. |
Anti-gitr antibodies
|
JP5837821B2
(ja)
*
|
2009-09-24 |
2015-12-24 |
中外製薬株式会社 |
抗体定常領域改変体
|
US8568726B2
(en)
|
2009-10-06 |
2013-10-29 |
Medimmune Limited |
RSV specific binding molecule
|
CA2776249C
(en)
|
2009-10-06 |
2021-01-19 |
Medimmune Ltd |
Rsv-specific binding molecule
|
TR201804897T4
(tr)
|
2009-10-07 |
2018-06-21 |
Macrogenics Inc |
Fukosi̇lasyon ölçüsünün deği̇şi̇mleri̇nden dolayi geli̇şmi̇ş efektör i̇şlevi̇ sergi̇leyen fc bölgesi̇ni̇ i̇çeren poli̇pepti̇tler ve bunlarin kullanimlarina yöneli̇k yöntemler
|
EP2493926B1
(en)
|
2009-10-27 |
2020-03-11 |
UCB Biopharma SRL |
Function modifying nav 1.7 antibodies
|
CN101875696B
(zh)
|
2009-11-11 |
2012-02-08 |
中国人民解放军军事医学科学院生物工程研究所 |
一种抗体及其制备方法与应用
|
ES2777901T3
(es)
|
2009-12-25 |
2020-08-06 |
Chugai Pharmaceutical Co Ltd |
Método de modificación de polipéptidos para purificar multímeros polipeptídicos
|
ES2592385T3
(es)
|
2009-12-29 |
2016-11-29 |
Aptevo Research And Development Llc |
Proteínas de unión a heterodímeros y usos de los mismos
|
WO2011091181A1
(en)
|
2010-01-20 |
2011-07-28 |
Tolerx, Inc. |
Immunoregulation by anti-ilt5 antibodies and ilt5-binding antibody fragments
|
CA2787783A1
(en)
|
2010-01-20 |
2011-07-28 |
Tolerx, Inc. |
Anti-ilt5 antibodies and ilt5-binding antibody fragments
|
TWI609698B
(zh)
|
2010-01-20 |
2018-01-01 |
Chugai Pharmaceutical Co Ltd |
穩定化的含抗體溶液製劑
|
US9624290B2
(en)
|
2010-01-28 |
2017-04-18 |
Ab Biosciences, Inc. |
Lowered affinity antibodies and methods of making the same
|
US20120315267A1
(en)
|
2010-02-09 |
2012-12-13 |
Glaxosmithkline Llc |
Novel uses
|
EP2536745B1
(en)
|
2010-02-19 |
2016-05-11 |
Xencor, Inc. |
Novel ctla4-ig immunoadhesins
|
ES2615732T3
(es)
|
2010-03-01 |
2017-06-08 |
Alexion Pharmaceuticals, Inc. |
Composiciones para tratar la enfermedad de Degos
|
KR101913440B1
(ko)
|
2010-03-02 |
2018-10-30 |
교와 핫꼬 기린 가부시키가이샤 |
개변 항체 조성물
|
EP2543730B1
(en)
|
2010-03-04 |
2018-10-31 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody constant region variant
|
JP5932670B2
(ja)
|
2010-03-11 |
2016-06-08 |
ライナット ニューロサイエンス コーポレイション |
pH依存性の抗原結合を有する抗体
|
JP2011184418A
(ja)
|
2010-03-11 |
2011-09-22 |
Tokyo Institute Of Technology |
親和性可変抗体
|
TW201206466A
(en)
|
2010-03-11 |
2012-02-16 |
Rinat Neuroscience Corp |
Antibodies with pH dependent antigen binding
|
TWI667346B
(zh)
|
2010-03-30 |
2019-08-01 |
中外製藥股份有限公司 |
促進抗原消失之具有經修飾的FcRn親和力之抗體
|
US9162161B2
(en)
|
2010-03-31 |
2015-10-20 |
Jsr Corporation |
Filler for affinity chromatography
|
US9150663B2
(en)
|
2010-04-20 |
2015-10-06 |
Genmab A/S |
Heterodimeric antibody Fc-containing proteins and methods for production thereof
|
TWI586806B
(zh)
|
2010-04-23 |
2017-06-11 |
建南德克公司 |
異多聚體蛋白質之製造
|
US20140206849A1
(en)
|
2010-04-30 |
2014-07-24 |
Alexion Pharmaceuticals, Inc. |
Antibodies having reduced immunogenicity in a human
|
EP2569337A1
(en)
|
2010-05-14 |
2013-03-20 |
Rinat Neuroscience Corp. |
Heterodimeric proteins and methods for producing and purifying them
|
JO3340B1
(ar)
|
2010-05-26 |
2019-03-13 |
Regeneron Pharma |
مضادات حيوية لـعامل تمايز النمو 8 البشري
|
WO2011149046A1
(ja)
|
2010-05-28 |
2011-12-01 |
独立行政法人国立がん研究センター |
膵癌治療剤
|
AR081556A1
(es)
|
2010-06-03 |
2012-10-03 |
Glaxo Group Ltd |
Proteinas de union al antigeno humanizadas
|
CA2806252C
(en)
|
2010-07-29 |
2019-05-14 |
Xencor, Inc. |
Antibodies with modified isoelectric points
|
JP2013537416A
(ja)
|
2010-08-13 |
2013-10-03 |
メディミューン リミテッド |
変異型Fc領域を含むモノマーポリペプチド及び使用方法
|
PE20131340A1
(es)
|
2010-08-16 |
2013-11-29 |
Amgen Inc |
Polipeptidos que enlazan miostatina, composiciones y metodos
|
CN103201293B
(zh)
|
2010-09-08 |
2016-04-27 |
哈洛齐梅公司 |
评估和鉴定或发展条件活性治疗蛋白的方法
|
JP6173911B2
(ja)
|
2010-09-10 |
2017-08-09 |
メディミューン リミテド |
抗体誘導体
|
CA2815266C
(en)
|
2010-11-05 |
2023-09-05 |
Zymeworks Inc. |
Stable heterodimeric antibody design with mutations in the fc domain
|
WO2012064627A2
(en)
|
2010-11-08 |
2012-05-18 |
Genentech, Inc. |
Subcutaneously administered anti-il-6 receptor antibody
|
KR102099580B1
(ko)
|
2010-11-17 |
2020-04-10 |
추가이 세이야쿠 가부시키가이샤 |
혈액응고 제viii 인자의 기능을 대체하는 기능을 갖는 다중특이성 항원 결합 분자
|
KR102385507B1
(ko)
|
2010-11-30 |
2022-04-12 |
추가이 세이야쿠 가부시키가이샤 |
복수 분자의 항원에 반복해서 결합하는 항원 결합 분자
|
WO2012073985A1
(ja)
|
2010-11-30 |
2012-06-07 |
中外製薬株式会社 |
細胞傷害誘導治療剤
|
CA2822288A1
(en)
|
2010-12-22 |
2012-06-28 |
Medimmune, Llc |
Anti-c5/c5a/c5adesr antibodies and fragments
|
WO2012093704A1
(ja)
|
2011-01-07 |
2012-07-12 |
中外製薬株式会社 |
抗体の物性を改善させる方法
|
WO2012132067A1
(ja)
|
2011-03-30 |
2012-10-04 |
中外製薬株式会社 |
抗原結合分子の血漿中滞留性と免疫原性を改変する方法
|
CN103492565B
(zh)
|
2011-02-25 |
2021-01-29 |
中外制药株式会社 |
FcγRIIb特异性Fc抗体
|
AU2012233313C1
(en)
|
2011-03-30 |
2017-08-03 |
Chugai Seiyaku Kabushiki Kaisha |
Method for altering plasma retention and immunogenicity of antigen-binding molecule
|
WO2012145238A2
(en)
|
2011-04-20 |
2012-10-26 |
Tolerx, Inc. |
Methods for reducing an adverse immune response to a foreign antigen in a human subject with anti-cd4 antibodies or cd4-binding fragments thereof or cd4-binding molecules
|
EP3508500A1
(en)
|
2011-04-29 |
2019-07-10 |
Apexigen, Inc. |
Anti-cd40 antibodies and methods of use
|
US8961981B2
(en)
|
2011-06-20 |
2015-02-24 |
Saint Louis University |
Targeting the neuromuscular junction for treatment
|
UA117901C2
(uk)
|
2011-07-06 |
2018-10-25 |
Ґенмаб Б.В. |
Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
|
WO2013012733A1
(en)
|
2011-07-15 |
2013-01-24 |
Biogen Idec Ma Inc. |
Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto
|
US20140335089A1
(en)
|
2011-09-30 |
2014-11-13 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule for promoting elimination of antigens
|
CN110655578A
(zh)
|
2011-09-30 |
2020-01-07 |
中外制药株式会社 |
诱导针对靶抗原的免疫应答的抗原结合分子
|
EP3939996A1
(en)
|
2011-09-30 |
2022-01-19 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
|
US10024867B2
(en)
|
2011-09-30 |
2018-07-17 |
Chugai Seiyaku Kabushiki Kaisha |
Ion concentration-dependent binding molecule library
|
TW201817745A
(zh)
|
2011-09-30 |
2018-05-16 |
日商中外製藥股份有限公司 |
具有促進抗原清除之FcRn結合域的治療性抗原結合分子
|
CN118290588A
(zh)
|
2011-10-27 |
2024-07-05 |
健玛保 |
异二聚体蛋白的生成
|
KR102168733B1
(ko)
|
2011-10-31 |
2020-10-23 |
추가이 세이야쿠 가부시키가이샤 |
중쇄와 경쇄의 회합이 제어된 항원 결합 분자
|
PL2773671T3
(pl)
|
2011-11-04 |
2022-01-24 |
Zymeworks Inc. |
Projekt stabilnego przeciwciała heterodimerycznego z mutacjami w domenie fc
|
WO2014067011A1
(en)
|
2012-11-02 |
2014-05-08 |
Zymeworks Inc. |
Crystal structures of heterodimeric fc domains
|
US20150056182A1
(en)
|
2011-11-30 |
2015-02-26 |
Chugai Seiyaku Kabushiki Kaisha |
Drug containing carrier into cell for forming immune complex
|
GB201203051D0
(en)
|
2012-02-22 |
2012-04-04 |
Ucb Pharma Sa |
Biological products
|
BR112014020821B1
(pt)
|
2012-02-24 |
2022-11-16 |
Chugai Seiyaku Kabushiki Kaisha |
Composição farmacêutica e método de produção de uma molécula de ligação a antígeno
|
ES2564281T3
(es)
|
2012-03-08 |
2016-03-21 |
F. Hoffmann-La Roche Ag |
Formulación de anticuerpos Abeta
|
AU2013234039B2
(en)
|
2012-03-13 |
2018-02-01 |
Novimmune S.A. |
Readily isolated bispecific antibodies with native immunoglobulin format
|
PT2825036T
(pt)
|
2012-03-16 |
2018-07-26 |
Regeneron Pharma |
Anticorpos de cadeia leve manipulados em histidina e roedores geneticamente modificados para gerar os mesmos
|
SI2825037T1
(sl)
|
2012-03-16 |
2019-08-30 |
Regeneron Pharmaceuticals, Inc. |
Glodavci, ki izražajo PH občutljiva zaporedja imunoglobulina
|
JP6280031B2
(ja)
|
2012-03-29 |
2018-02-14 |
中外製薬株式会社 |
抗lamp5抗体およびその利用
|
AU2013237929B2
(en)
|
2012-03-29 |
2017-09-14 |
Novimmune S.A. |
Anti-TLR4 antibodies and uses thereof
|
TWI619729B
(zh)
|
2012-04-02 |
2018-04-01 |
再生元醫藥公司 |
抗-hla-b*27抗體及其用途
|
MX360110B
(es)
|
2012-04-20 |
2018-10-23 |
Merus Nv |
Metodos y medios para la produccion de moleculas de tipo ig.
|
KR20150004856A
(ko)
|
2012-04-20 |
2015-01-13 |
이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 |
Cd3 결합 폴리펩타이드
|
WO2013166099A1
(en)
|
2012-05-01 |
2013-11-07 |
Glaxosmithkline Llc |
Novel antibodies
|
US9255154B2
(en)
|
2012-05-08 |
2016-02-09 |
Alderbio Holdings, Llc |
Anti-PCSK9 antibodies and use thereof
|
KR20150016579A
(ko)
|
2012-05-30 |
2015-02-12 |
추가이 세이야쿠 가부시키가이샤 |
표적 조직 특이적 항원 결합 분자
|
EP2857419B1
(en)
|
2012-05-30 |
2021-01-13 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule for eliminating aggregated antigens
|
CN104520331B
(zh)
|
2012-06-01 |
2018-09-07 |
美国政府(由卫生和人类服务部的部长所代表) |
磷脂酰肌醇蛋白聚糖3的高亲和力单克隆抗体及其用途
|
US8992913B2
(en)
|
2012-06-15 |
2015-03-31 |
Pfizer Inc. |
Antagonist antibodies against GDF-8 and uses therefor
|
SG10201605703TA
(en)
|
2012-07-06 |
2016-09-29 |
Genmab Bv |
Dimeric protein with triple mutations
|
NZ704771A
(en)
|
2012-08-13 |
2018-02-23 |
Regeneron Pharma |
Anti-pcsk9 antibodies with ph-dependent binding characteristics
|
US9133269B2
(en)
|
2012-08-24 |
2015-09-15 |
Anaptysbio, Inc. |
Humanized antibodies directed against complement protein C5
|
EP2889377B1
(en)
|
2012-08-24 |
2020-01-08 |
Chugai Seiyaku Kabushiki Kaisha |
Fcyriib-specific fc region variant
|
TWI660972B
(zh)
|
2012-09-10 |
2019-06-01 |
愛爾蘭商尼歐托普生物科學公司 |
抗mcam抗體及相關使用方法
|
CA2884730C
(en)
|
2012-09-13 |
2023-07-04 |
Bristol-Myers Squibb Company |
Fibronectin based scaffold domain proteins that bind to myostatin
|
TW201418707A
(zh)
|
2012-09-21 |
2014-05-16 |
Alexion Pharma Inc |
補體組分c5拮抗劑之篩選分析
|
SG11201502451QA
(en)
|
2012-09-27 |
2015-05-28 |
Merus B V |
BISPECIFIC IgG ANTIBODIES AS T CELL ENGAGERS
|
US9714291B2
(en)
|
2012-10-05 |
2017-07-25 |
Kyowa Hakko Kirin Co., Ltd |
Heterodimer protein composition
|
SG10201704616SA
(en)
|
2012-11-06 |
2017-07-28 |
Scholar Rock Inc |
Compositions and methods for modulating cell signaling
|
CN103833852A
(zh)
|
2012-11-23 |
2014-06-04 |
上海市肿瘤研究所 |
针对磷脂酰肌醇蛋白多糖-3和t细胞抗原的双特异性抗体
|
CA2896076C
(en)
|
2012-12-21 |
2022-12-06 |
Aveo Pharmaceuticals, Inc. |
Anti-gdf15 antibodies
|
US9701759B2
(en)
|
2013-01-14 |
2017-07-11 |
Xencor, Inc. |
Heterodimeric proteins
|
KR20150110659A
(ko)
|
2013-01-24 |
2015-10-02 |
글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 |
Tnf-알파 항원-결합 단백질
|
BR112015018438A2
(pt)
|
2013-01-31 |
2017-07-18 |
Seoul Nat Univ R&Db Foundation |
anticorpo contra c5 e método para prevenir e tratar doenças relacionadas a complemento
|
US9481725B2
(en)
|
2013-03-14 |
2016-11-01 |
Alderbio Holdings, Llc |
Antibodies to HGF and compositions containing
|
BR112015022119A2
(pt)
|
2013-03-15 |
2017-08-29 |
Abbvie Biotherapeutics Inc |
Polipeptídeo, composto conjugado, composição farmacêutica, ácido nucleico, vetor, células hospedeiras procariótica e eucariótica, método de produção de um polipeptídeo, e, método de tratamento
|
KR102211176B1
(ko)
|
2013-03-15 |
2021-02-01 |
젠코어 인코포레이티드 |
이형이량체 단백질
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
US20160038588A1
(en)
|
2013-03-15 |
2016-02-11 |
Amgen Inc. |
Myostatin Antagonism in Human Subjects
|
US20160031985A1
(en)
|
2013-03-15 |
2016-02-04 |
Katherine S. Bowdish |
Charge-engineered antibodies or compositions of penetration-enhanced targeting proteins and methods of use
|
US20160051673A1
(en)
|
2013-03-29 |
2016-02-25 |
Alexion Pharmaceuticals, Inc. |
Compositions and methods for increasing the serum half-life of a therapeutic agent targeting complement c5
|
AU2014250434B2
(en)
|
2013-04-02 |
2019-08-08 |
Chugai Seiyaku Kabushiki Kaisha |
Fc region variant
|
PL2981822T4
(pl)
|
2013-05-06 |
2021-07-12 |
Scholar Rock, Inc. |
Kompozycje i sposoby modulacji czynnika wzrostu
|
SG11201509284VA
(en)
|
2013-05-17 |
2015-12-30 |
Centre Nat Rech Scient |
Anti-cxcl1, cxcl7 and cxcl8 antibodies and their applications
|
EP3004174B1
(en)
|
2013-05-31 |
2019-04-17 |
Zymeworks Inc. |
Heteromultimers with reduced or silenced effector function
|
EP4067383A1
(en)
|
2013-07-25 |
2022-10-05 |
Cytomx Therapeutics Inc. |
Multispecific antibodies, multispecific activatable antibodies and methods of using the same
|
BR112016002198A2
(pt)
|
2013-08-14 |
2017-09-12 |
Novartis Ag |
métodos de tratamento de miosite por corpos de inclusão esporádica
|
EP3033093A1
(en)
|
2013-08-16 |
2016-06-22 |
Alexion Pharmaceuticals, Inc. |
Treatment of graft rejection by administering a complement inhibitor to an organ prior to transplant
|
AU2014325063B2
(en)
|
2013-09-27 |
2019-10-31 |
Chugai Seiyaku Kabushiki Kaisha |
Method for producing polypeptide heteromultimer
|
EP2853898B1
(en)
|
2013-09-27 |
2017-01-04 |
Medizinische Hochschule Hannover |
Analysis of myostatin in serum
|
EP3940065A1
(en)
|
2013-09-30 |
2022-01-19 |
Chugai Seiyaku Kabushiki Kaisha |
Method for producing antigen-binding molecule using modified helper phage
|
NZ720161A
(en)
|
2013-11-04 |
2022-07-29 |
Ichnos Sciences SA |
Production of t cell retargeting hetero-dimeric immunoglobulins
|
EP3100056A2
(en)
|
2014-01-27 |
2016-12-07 |
Novartis AG |
Biomarkers predictive of muscle atrophy, method and use
|
RU2019119862A
(ru)
|
2014-02-20 |
2019-07-15 |
Аллерган, Инк. |
Антитела к компоненту комплемента c5
|
NZ711451A
(en)
|
2014-03-07 |
2016-05-27 |
Alexion Pharma Inc |
Anti-c5 antibodies having improved pharmacokinetics
|
AU2015244814B2
(en)
|
2014-04-07 |
2020-12-24 |
Chugai Seiyaku Kabushiki Kaisha |
Immunoactivating antigen-binding molecule
|
TW201622746A
(zh)
|
2014-04-24 |
2016-07-01 |
諾華公司 |
改善或加速髖部骨折術後身體復原之方法
|
AU2015260230A1
(en)
|
2014-05-13 |
2016-11-17 |
Chugai Seiyaku Kabushiki Kaisha |
T cell-redirected antigen-binding molecule for cells having immunosuppression function
|
TW201625299A
(zh)
|
2014-06-20 |
2016-07-16 |
Chugai Pharmaceutical Co Ltd |
用於因第viii凝血因子及/或活化的第viii凝血因子的活性降低或欠缺而發病及/或進展的疾病之預防及/或治療之醫藥組成物
|
CA2953714C
(en)
|
2014-06-30 |
2021-05-18 |
Ralf Guenther |
Anti-tnfa antibodies with ph-dependent antigen binding
|
MA40764A
(fr)
|
2014-09-26 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
Agent thérapeutique induisant une cytotoxicité
|
JP6630036B2
(ja)
|
2014-09-30 |
2020-01-15 |
Jsr株式会社 |
標的物の精製方法、及び、ミックスモード用担体
|
WO2016073879A2
(en)
|
2014-11-06 |
2016-05-12 |
Scholar Rock, Inc. |
Transforming growth factor-related antibodies and uses thereof
|
AU2015342936B2
(en)
|
2014-11-06 |
2020-10-08 |
Scholar Rock, Inc. |
Anti-pro/latent-Myostatin antibodies and uses thereof
|
BR112017011411A2
(pt)
|
2014-12-08 |
2018-02-14 |
Novartis Ag |
antagonistas da miostatina ou da activina para o tratamento da sarcopenia
|
TWI831538B
(zh)
|
2014-12-19 |
2024-02-01 |
日商中外製藥股份有限公司 |
抗肌抑素之抗體、含變異Fc區域之多胜肽及使用方法
|
SG10201710322VA
(en)
|
2014-12-19 |
2018-02-27 |
Chugai Pharmaceutical Co Ltd |
Anti-c5 antibodies and methods of use
|
EP3247723A1
(en)
|
2015-01-22 |
2017-11-29 |
Chugai Seiyaku Kabushiki Kaisha |
A combination of two or more anti-c5 antibodies and methods of use
|
EA201791754A1
(ru)
|
2015-02-05 |
2019-01-31 |
Чугаи Сейяку Кабусики Кайся |
АНТИТЕЛА, СОДЕРЖАЩИЕ ЗАВИСЯЩИЙ ОТ КОНЦЕНТРАЦИИ ИОНОВ АНТИГЕНСВЯЗЫВАЮЩИЙ ДОМЕН, ВАРИАНТЫ Fc-ОБЛАСТИ, IL-8-СВЯЗЫВАЮЩИЕ АНТИТЕЛА И ИХ ПРИМЕНЕНИЯ
|
RU2730590C2
(ru)
|
2015-02-27 |
2020-08-24 |
Чугаи Сейяку Кабусики Кайся |
Композиция для лечения заболеваний, связанных с ил-6
|
JP6944375B2
(ja)
|
2015-03-31 |
2021-10-06 |
アレクシオン ファーマシューティカルズ, インコーポレイテッド |
発作性夜間血色素尿症(pnh)患者の亜集団の同定および処置
|
WO2016159213A1
(ja)
|
2015-04-01 |
2016-10-06 |
中外製薬株式会社 |
ポリペプチド異種多量体の製造方法
|
IL255010B2
(en)
|
2015-04-15 |
2024-01-01 |
Regeneron Pharma |
Methods for increasing strength and functionality with GDF8 inhibitors
|
MX2017010734A
(es)
|
2015-04-17 |
2017-12-04 |
Hoffmann La Roche |
Terapia de combinacion con factores de coagulacion y anticuepos multiespecificos.
|
JP2018123055A
(ja)
|
2015-04-24 |
2018-08-09 |
公立大学法人奈良県立医科大学 |
血液凝固第viii因子(fviii)の機能を代替する多重特異性抗原結合分子を含有する、血液凝固第xi因子(fxi)異常症の予防および/または治療に用いられる医薬組成物
|
EP3288586A1
(en)
|
2015-05-01 |
2018-03-07 |
Alexion Pharmaceuticals, Inc. |
Efficacy of an anti-c5 antibody in the prevention of antibody mediated rejection in sensitized recipients of kindney thansplant
|
EP3313437A1
(en)
|
2015-06-26 |
2018-05-02 |
Alexion Pharmaceuticals, Inc. |
A method for treating a patient in compliance with vaccination with eculizumab or an eculizumab variant
|
US10940126B2
(en)
|
2015-07-03 |
2021-03-09 |
Camilla Svensson |
Inhibition of IL-8 in the treatment of pain and/or bone loss
|
DK3350220T3
(da)
|
2015-09-15 |
2021-07-12 |
Scholar Rock Inc |
Anti-pro/latente-myostatin-antistoffer og anvendelser deraf
|
KR101920175B1
(ko)
|
2015-09-18 |
2018-11-19 |
추가이 세이야쿠 가부시키가이샤 |
Il-8에 결합하는 항체 및 그의 사용
|
TW201718014A
(zh)
|
2015-10-12 |
2017-06-01 |
諾華公司 |
C5抑制劑於移植相關微血管病之用途
|
JP6088703B1
(ja)
|
2015-12-18 |
2017-03-01 |
中外製薬株式会社 |
抗c5抗体および使用方法
|
KR20230027321A
(ko)
|
2015-12-18 |
2023-02-27 |
추가이 세이야쿠 가부시키가이샤 |
항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
|
EP3394098A4
(en)
|
2015-12-25 |
2019-11-13 |
Chugai Seiyaku Kabushiki Kaisha |
ANTI-MYOSTATIN ANTIBODIES AND METHODS OF USE
|
KR20180091918A
(ko)
|
2015-12-28 |
2018-08-16 |
추가이 세이야쿠 가부시키가이샤 |
Fc 영역 함유 폴리펩타이드의 정제를 효율화하기 위한 방법
|
WO2017120523A2
(en)
|
2016-01-08 |
2017-07-13 |
Scholar Rock, Inc. |
Anti-pro/latent myostatin antibodies and methods of use thereof
|
US20190023775A1
(en)
|
2016-01-11 |
2019-01-24 |
Alexion Pharmaceuticals, Inc. |
Dosage and administration of anti-c5 antibodies for treatment
|
TWI797073B
(zh)
|
2016-01-25 |
2023-04-01 |
德商安美基研究(慕尼黑)公司 |
包含雙特異性抗體建構物之醫藥組合物
|
KR101834708B1
(ko)
|
2016-03-14 |
2018-03-06 |
추가이 세이야쿠 가부시키가이샤 |
암의 치료에 이용하기 위한 세포상해 유도 치료제
|
JP6175590B1
(ja)
|
2016-03-14 |
2017-08-02 |
中外製薬株式会社 |
癌の治療に用いるための細胞傷害誘導治療剤
|
CR20180554A
(es)
|
2016-04-28 |
2019-01-10 |
Chugai Pharmaceutical Co Ltd |
Preparaciones que contienen anticuerpos
|
IL301468A
(en)
|
2016-06-13 |
2023-05-01 |
Scholar Rock Inc |
Use of myostatin inhibitors and combined treatments
|
CA3019904A1
(en)
|
2016-06-17 |
2017-12-21 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-myostatin antibodies and methods of use
|
UA126561C2
(uk)
|
2016-06-17 |
2022-11-02 |
Чугаі Сейяку Кабусікі Кайся |
Застосування антитіла проти с5
|
IL264626B
(en)
|
2016-08-05 |
2022-07-01 |
Chugai Pharmaceutical Co Ltd |
A preparation for the prevention or treatment of diseases related to il-8
|
MY201148A
(en)
|
2017-01-31 |
2024-02-07 |
Hoffmann La Roche |
A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
|
BR112019019108A2
(pt)
|
2017-03-14 |
2020-04-22 |
Five Prime Therapeutics, Inc. |
anticorpos, ácido nucleico, composições, célula, métodos para preparar de um anticorpo, para tratar um sujeito com câncer, para tratar uma doença infecciosa, para tratar uma inflamação, para identificar um ab, para melhorar a eficácia antitumoral de um ab, para melhorar a farmacocinética de um anticorpo, para seleção de um anticorpo, para melhorar a eficácia de anticorpos, para isolar anticorpos e para detectar vista em uma amostra
|
JP7209298B2
(ja)
|
2017-03-31 |
2023-01-20 |
公立大学法人奈良県立医科大学 |
血液凝固第viii因子の機能を代替する多重特異性抗原結合分子を含有する、血液凝固第ix因子異常症の予防および/または治療に用いられる医薬組成物
|
JP7518764B2
(ja)
|
2017-10-26 |
2024-07-18 |
アレクシオン ファーマシューティカルズ, インコーポレイテッド |
発作性夜間ヘモグロビン尿症(PNH)および非典型溶血性***症候群(aHUS)の処置のための抗C5抗体の投薬量および投与
|
WO2019112984A1
(en)
|
2017-12-04 |
2019-06-13 |
Ra Pharmaceuticals, Inc. |
Modulators of complement activity
|
US20210301004A1
(en)
|
2018-08-01 |
2021-09-30 |
Chugai Seiyaku Kabushiki Kaisha |
A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
|